Skip to main content

Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with metastatic Gastrointestinal Stromal Tumours

Objective

Gastrointestinal stromal tumours (GIST) are a rare disease that metastasises in up to 85% of patients with subsequent median progression-free survival (PFS) of only around 30 months. Tumours are characterised by activating mutations in the KIT or the PDGFRA gene and therefore treatment is mainly based on tyrosine kinase inhibitors designed to block these mutated receptors. However, drug resistance is often based on mutations changing the conformity of the receptor, leaving little effective therapeutic options to these patients. To date, second line chemotherapy offers a median PFS of 6-9 months and external beam radiotherapy is limited by organs at risk close to the tumour. Alternative approaches such as endoradiotherapy or minimally-invasive ablation techniques are effective for local control but are inconsistently used and are not tailored to the individual patient's type of disease. To address these issues, we propose a closed-loop personalised treatment concept combining endoscopic-assisted tissue sampling, inline biotechnology and targeted molecular PET imaging probe development combined with minimally-invasive treatment monitored by new functional and metabolic MR imaging techniques. A consistent value chain across European academic centres, research institutes and SMEs will be established for mass spectrometry of tumours, linkage of radiochemical molecular imaging probes, design of new immunocompromised animal models and targeted therapeutic radiopharmaceuticals. This closed-loop platform will minimise fragmentation of treatment approaches by a coherent molecular-based multimodality concept, thus providing new treatment options. On a larger scale, the MITIGATE platform can be expanded to further patient cohorts with oligometastatic diseases such as other sarcomas or renal cell carcinoma. For SMEs the access to new animal models and ligands along with translation into clinical practice will strengthen their market share for new probes and imaging technology.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance
  • /natural sciences/biological sciences/genetics and heredity/mutation
  • /natural sciences/chemical sciences/analytical chemistry/mass spectrometry

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Address
Seminarstrasse 2
69117 Heidelberg
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 584 368
Administrative Contact
Melanie Stein (Mrs.)

Participants (9)

EIBIR GEMEINNUTZIGE GMBH ZUR FORDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG
Austria
EU contribution
€ 464 000
Address
Neutorgasse 9/2
1010 Wien
Activity type
Research Organisations
Administrative Contact
Pamela Zolda (Dr.)
MEDIZINISCHE UNIVERSITAT INNSBRUCK
Austria
EU contribution
€ 331 400
Address
Christoph Probst Platz 1
6020 Innsbruck
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Werner Jaschke (Prof.)
UNIVERSITA DEGLI STUDI DI TORINO
Italy
EU contribution
€ 130 950
Address
Via Giuseppe Verdi 8
10124 Torino
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Giorgio Inghirami (Prof.)
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Germany
EU contribution
€ 405 422
Address
Hansastrasse 27C
80686 Munchen
Activity type
Research Organisations
Administrative Contact
Walter Krause (Mr.)
CAGE CHEMICALS SRL
Italy
EU contribution
€ 307 795
Address
Via Bovio 6
28100 Novara
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Camilla Cavallotti (Dr.)
Advanced Accelerator Applications
France
EU contribution
€ 449 640
Address
Rue Diesel 20
01630 Saint Genis Pouilly
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jean Philippe Meunier (Dr.)
RAPID BIOMEDIZINISCHE GERATE RAPID BIOMEDICAL GMBH
Germany
EU contribution
€ 329 488
Address
Kettelerstrasse 3-11 Pav 2-4
97222 Rimpar
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Kay Lipinski (Mr.)
STEMCELL TECHNOLOGIES SARL
France
EU contribution
€ 261 690
Address
Minipar Polytec Rue Des Berges 40
38000 Grenoble
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Marie-Claude Genevay (Mrs.)
HOCHSCHULE MANNHEIM
Germany
EU contribution
€ 229 500
Address
Paul-wittsack-strasse 10
68163 Mannheim
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Winfried Hugo (Mr.)